1,633 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
AMGN Amgen Inc. $200.81 $129.98B Buy
Article Searches
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III http://www.zacks.com/stock/news/349758/amgen-allergans-rituxan-biosimilar-meets-goal-in-phase-iii?cid=CS-ZC-FT-349758 Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Is a Surprise in the Cards for Novartis (NVS) in Q4 Earnings? http://www.zacks.com/stock/news/349556/is-a-surprise-in-the-cards-for-novartis-nvs-in-q4-earnings?cid=CS-ZC-FT-349556 Jan 24, 2019 - Swiss-giant Novartis (NVS) is set to report fourth-quarter earnings on Jan 30. While the pharma business should maintain growth, the generic division is expected to lag.
The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio http://www.zacks.com/stock/news/349485/the-zacks-analyst-blog-highlights-celgene-regeneron-pharmaceuticals-amgen-alnylam-pharmaceuticals-and-bluebird-bio?cid=CS-ZC-FT-349485 Jan 24, 2019 - The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio
Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs http://www.zacks.com/stock/news/348985/biotech-stock-roundup-amgen-vertex-get-ec-nod-for-label-expansion-of-drugs?cid=CS-ZC-FT-348985 Jan 23, 2019 - A low key week for the biotech sector with regular drug approvals and pipeline updates.
Top Analyst Reports for Bank of America, Merck & Netflix http://www.zacks.com/research-daily/206820/top-analyst-reports-for-bank-of-america-merck-netflix?cid=CS-ZC-FT-206820 Jan 21, 2019 - Top Analyst Reports for Bank of America, Merck & Netflix
What's in Store for Bristol-Myers (BMY) in Q4 Earnings? http://www.zacks.com/stock/news/348553/whats-in-store-for-bristol-myers-bmy-in-q4-earnings?cid=CS-ZC-FT-348553 Jan 21, 2019 - Performance of Opdivo and the recently announced acquisition of Celgene Corporation will be key areas of focus for the investors when Bristol-Myers (BMY) reports fourth-quarter results.
The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen http://feeds.benzinga.com/~r/benzinga/~3/-qf8Lb6Vq5o/the-daily-biotech-pulse-revance-common-stock-offering-adcom-catalyst- Jan 16, 2019 -

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peak

(Biotech Stocks Hitting 52-week highs Jan. 15)

read more

For Children With Cancer, Hope for New Treatments https://www.wsj.com/articles/for-children-with-cancer-hope-for-new-treatments-11547561004?mod=WSJ_GoogleNews Jan 15, 2019 - A new law requiring pharmaceuticals companies to test cancer drugs on children as well as adults is raising hopes of more therapies.
Why AbbVie Believes In Life After (Humira's) Death https://seekingalpha.com/article/4233472-abbvie-believes-life-humiras-death?source=feed_sector_healthcare Jan 15, 2019 - ABBV has been mired in a bear market, in large part due to worse-than-expected competition to Humira from biosimilars in the EU.U.S. biosimilars to Humira will enter in 2023, though a competitor is tr
What's in Store for Merck in 2019 After a Solid Run in '18? http://www.zacks.com/stock/news/347164/whats-in-store-for-merck-in-2019-after-a-solid-run-in-18?cid=CS-ZC-FT-347164 Jan 14, 2019 - Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.

Pages: 1234567891011...164

<<<Page 6>